Zacks Investment Research downgraded Chemours Co. (CC) from "Strong-Buy" to "Strong Sell" in a report issued on Tuesday, August 11. The downgrade reverses the firm's outlook on the specialty chemicals company.
The downgrade follows a disappointing second-quarter financial report from early August. Chemours missed consensus estimates for both earnings and revenue. Earlier in the week, UBS also downgraded the stock. BMO Capital Markets and Morgan Stanley lowered their respective price targets.